Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-08-05

Fate Therapeutics (FATE)

CEO Bahram Valamehr was paid $2,248,568 in fiscal year 2025, ↓ down 37.3% from fiscal year 2024 (SEC filing 0001193125-26-177094 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$2,248,568 ↓
Bahram Valamehr total, FY2025
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
97.03%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

FATE's next annual pay disclosure, estimated May 1, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Bahram Valamehr$600,000$0$0$1,283,868$360,000$0$4,700$2,248,568
President, Chief Executive Officer and Director
Cindy Tahl520,000092,400286,896208,00004,7001,111,996
Chief Legal & Compliance Officer and Corporate Secretary
Kamal Adawi99,0000115,500456,00039,60004,700714,800
Chief Financial Officer and Treasurer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Bahram Valamehr$2,248,568$3,584,600$2,986,615↓ −1,336,032
Cindy Tahl1,111,9963,421,1002,824,498↓ −2,309,104
Kamal Adawi714,800———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Fate Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper FATE reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against FATE
11 companies name FATE as a compensation peer

The list of companies that name FATE as a peer is temporarily unavailable — recheck shortly.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Kamal AdawiCFO$714,800
Cindy TahlGeneral Counsel$1,111,996
Bahram ValamehrCEO$2,248,568
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
John D. MendleinFormer director (through FY2025)$92,586
Karin JoossIndependent Director$118,961
Laura J. HamillDirector—
Matthew C. AbernethyIndependent Director$151,612
Michael LeeIndependent Director$104,086
Neelufar MozaffarianFormer director (through FY2025)$96,336
Robert S. EpsteinIndependent Director$123,711
Shefali AgarwalIndependent Director$115,086
Timothy P. CoughlinFormer director (through FY2025)$26,225
William H. RastetterChair of the Board$142,982
Yuan XuIndependent Director$111,524
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
William H. RastetterDirector2026-05-05A25,000$2$42,250CommonForm 4 ↗
William H. RastetterDirector2026-05-05A25,00000Derivative, Class A CommonForm 4 ↗
Robert S. EpsteinDirector2026-05-05A25,00000Derivative, Class A CommonForm 4 ↗
Robert S. EpsteinDirector2026-05-05A25,000242,250CommonForm 4 ↗
Cindy TahlSee Remarks2026-05-06A122,2201161,330CommonForm 4 ↗
Cindy TahlSee Remarks2026-05-06D44,44400Derivative, Class A CommonForm 4 ↗
Cindy TahlSee Remarks2026-05-06D122,22000Derivative, Class A CommonForm 4 ↗
Cindy TahlSee Remarks2026-05-06A44,444146,666CommonForm 4 ↗
Bahram ValamehrDirector2026-05-20D28,946254,482Common, open-market saleForm 4 ↗
Cindy TahlSee Remarks2026-05-20D25,590248,084Common, open-market saleForm 4 ↗
William H. RastetterDirector2026-06-12A87,90000Derivative, Class A CommonForm 4 ↗
Matthew C. AbernethyDirector2026-06-12A87,90000Derivative, Class A CommonForm 4 ↗
Shefali AgarwalDirector2026-06-12A87,90000Derivative, Class A CommonForm 4 ↗
Michael LeeDirector2026-06-12A87,90000Derivative, Class A CommonForm 4 ↗
Redmile Group, LLCDirector2026-06-12A87,90000Derivative, Class A CommonForm 4 ↗
Yuan XuDirector2026-06-12A87,90000Derivative, Class A CommonForm 4 ↗
Laura J. HamillDirector2026-06-12A175,80000Derivative, Class A CommonForm 4 ↗
Robert S. EpsteinDirector2026-06-12A87,90000Derivative, Class A CommonForm 4 ↗
Karin JoossDirector2026-06-12A87,90000Derivative, Class A CommonForm 4 ↗
Cindy TahlSee Remarks2026-08-04D38,800295,405Common, open-market saleForm 4 ↗
Bahram ValamehrDirector2026-08-04D43,9472108,101Common, open-market saleForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Cindy TahlRSU—————$92,400
Cindy TahlOption—————286,896
Kamal AdawiOption—————456,000
Kamal AdawiRSU—————115,500
Bahram ValamehrOption—————1,283,868
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Cindy Tahl$92,400$0$286,8960.0%
Kamal Adawi115,5000456,0000.0%
Bahram Valamehr001,283,8680.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Bahram ValamehrOption902,7791.25—
Kamal AdawiOption375,0001.54—
Cindy TahlOption153,4786.76—
Bahram ValamehrOption1,10639.87—
Bahram ValamehrOption12,5016.77—
Bahram ValamehrOption162,5016.76—
Cindy TahlOption1,10639.87—
Cindy TahlOption11,8066.77—
Cindy TahlOption190,9751.32—
05

Incentive-plan design — the Compensation Discussion & Analysis

Each year, the Compensation Committee reviews the Company's compensation policies and programs to ensure that these policies and programs enhance shareholder value, align pay and performance, and attract and retain top executive talent.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)—
Independent consultantAon's Human Capital Solutions practice (Radford)
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-1259,168,6891,808,66973,30497.03%Passed
20242024-06-0765,401,63525,615,148433,96471.86%Passed
20232023-06-0673,720,4422,955,50361,93896.15%Passed
20222022-06-0975,409,6099,055,375281,39589.28%Passed
20212021-06-0275,621,3211,509,26734,08398.04%Passed
20202020-05-0156,002,8843,656,40755,16693.87%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-1297.03%a
20242024-06-0771.86%b
20232023-06-0696.15%c

a. Approved under the standard stated in the filing — “If 2 Table of Contents you abstain from voting on this matter, your shares will not be counted as "votes cast" with respect to such matter, and the abstention will have no effect on the proposal.”.

b. Approved under the standard stated in the filing — “If you abstain from voting on this matter, your shares will not be counted as "votes cast" with respect to such matter, and the abstention will have no effect on the proposal.”.

c. Approved under the standard stated in the filing — “If you abstain from voting on this matter, your shares will not be counted as "votes cast" with respect to such matter, and the abstention will have no effect on the proposal.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)—
CEO total compensation—
Median employee compensation—
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Matthew C. AbernethyIndependent · Audit (Chair) · Newly elected$35,440$0$116,172—$0$151,612
William H. RastetterIndependent · Board Chair · Audit84,896058,086—0142,982
Robert S. EpsteinIndependent · Audit · Compensation · Nominating/Governance (Chair)65,625058,086—0123,711
Karin JoossIndependent · Compensation (Chair) · Science & Technology60,875058,086—0118,961
Shefali AgarwalIndependent · Nominating/Governance · Science & Technology (Chair)57,000058,086—0115,086
Yuan XuIndependent · Compensation · Science & Technology53,438058,086—0111,524
Michael LeeIndependent · Science & Technology46,000058,086—0104,086
Neelufar MozaffarianIndependent · Departed during FY38,250058,086—096,336
John D. MendleinIndependent · Departed during FY34,500058,086—092,586
Timothy P. CoughlinIndependent · Not standing for re-election · Departed during FY26,2250——026,225
Laura J. HamillNewly elected000—00
Bahram ValamehrEmployee director000—00
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)15,000 / 12,000 / 10,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$502,249
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$502,249

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Fate Therapeutics2025Bahram Valamehr$600,000$0$1,283,868$360,000$2,248,568

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Fate Therapeutics in fiscal 2025?
As disclosed, Bahram Valamehr (President, Chief Executive Officer and Director) was the highest-paid executive at Fate Therapeutics in fiscal 2025, with total compensation of $2,248,568.
How did shareholders vote on Fate Therapeutics's executive compensation?
As disclosed, 97.03% of shareholders supported Fate Therapeutics's executive compensation in the latest say-on-pay vote.
How much does Fate Therapeutics spend in total on board compensation for fiscal 2025?
As disclosed, Fate Therapeutics reported total board compensation of $502,249 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Bahram ValamehrDEF 14A2026-04-240001193125-26-177094Section “2025 Summary Compensation Table”. As printed: 2,248,568. Filing ↗machine: r2 · c31 · span 391551–391560
2Section 01, Cindy TahlDEF 14A2026-04-240001193125-26-177094Section “2025 Summary Compensation Table”. As printed: 1,111,996. Filing ↗machine: r6 · c31 · span 400096–400105
3Section 01, Kamal AdawiDEF 14A2026-04-240001193125-26-177094Section “2025 Summary Compensation Table”. As printed: 714,800. Filing ↗machine: t109 · r4 · c31 · span 396362–396369
4Section 03, Cindy Tahl RSUDEF 14A2026-04-240001193125-26-177094Section “FOR THE APPROVAL, ONNON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY&” · grants of plan-based awards table. Filing ↗machine: t99 · r6 · c11 · span 346240–346246
5Section 03, Cindy Tahl OptionDEF 14A2026-04-240001193125-26-177094Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t109 · r6 · c19 · span 399423–399430
6Section 03, Kamal Adawi OptionDEF 14A2026-04-240001193125-26-177094Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t109 · r4 · c19 · span 395690–395697
7Section 03, Kamal Adawi RSUDEF 14A2026-04-240001193125-26-177094Section “FOR THE APPROVAL, ONNON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY&” · grants of plan-based awards table. Filing ↗machine: t99 · r5 · c11 · span 344712–344719
8Section 03, Bahram Valamehr OptionDEF 14A2026-04-240001193125-26-177094Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t109 · r2 · c19 · span 390876–390885
9Section 07, pay ratio10-K2026-02-260001193125-26-073699Section “CEO Pay Ratio”. As printed: —. Filing ↗
10Section 08, Matthew C. AbernethyDEF 14A2026-04-240001193125-26-177094Section “Director Compensation”. As printed: 151,612. Filing ↗machine: span 241044–241051
11Section 08, William H. RastetterDEF 14A2026-04-240001193125-26-177094Section “Director Compensation”. As printed: 142,982. Filing ↗
12Section 08, Robert S. EpsteinDEF 14A2026-04-240001193125-26-177094Section “Director Compensation”. As printed: 123,711. Filing ↗machine: span 244844–244851
13Section 08, Karin JoossDEF 14A2026-04-240001193125-26-177094Section “Director Compensation”. As printed: 118,961. Filing ↗machine: span 246104–246111
14Section 08, Shefali AgarwalDEF 14A2026-04-240001193125-26-177094Section “Director Compensation”. As printed: 115,086. Filing ↗machine: span 242292–242299
15Section 08, Yuan XuDEF 14A2026-04-240001193125-26-177094Section “Director Compensation”. As printed: 111,524. Filing ↗machine: span 252370–252377
16Section 08, Michael LeeDEF 14A2026-04-240001193125-26-177094Section “Director Compensation”. As printed: 104,086. Filing ↗machine: span 247332–247339
17Section 08, Neelufar MozaffarianDEF 14A2026-04-240001193125-26-177094Section “Director Compensation”. As printed: 96,336. Filing ↗
18Section 08, John D. MendleinDEF 14A2026-04-240001193125-26-177094Section “Director Compensation”. As printed: 92,586. Filing ↗machine: span 248603–248609
19Section 08, Timothy P. CoughlinDEF 14A2026-04-240001193125-26-177094Section “Director Compensation”. As printed: 26,225. Filing ↗machine: span 242829–242835
20Section 08, Laura J. HamillDEF 14A2026-04-240001193125-26-177094Section “Director Compensation”. As printed: 0. Filing ↗
21Section 08, Bahram ValamehrDEF 14A2026-04-240001193125-26-177094Section “Director Compensation”. As printed: 0. Filing ↗
22Section 02, William H. Rastetter 2026-05-05Form 42026-05-060001193125-26-208891Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, William H. Rastetter 2026-05-05Form 42026-05-060001193125-26-208891Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Robert S. Epstein 2026-05-05Form 42026-05-060001193125-26-208899Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Robert S. Epstein 2026-05-05Form 42026-05-060001193125-26-208899Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Cindy Tahl 2026-05-06Form 42026-05-070001193125-26-211820Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Cindy Tahl 2026-05-06Form 42026-05-070001193125-26-211820Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Cindy Tahl 2026-05-06Form 42026-05-070001193125-26-211820Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Cindy Tahl 2026-05-06Form 42026-05-070001193125-26-211820Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Bahram Valamehr 2026-05-20Form 42026-05-210001193125-26-234380Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Cindy Tahl 2026-05-20Form 42026-05-210001193125-26-234390Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, William H. Rastetter 2026-06-12Form 42026-06-150001193125-26-271072Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Matthew C. Abernethy 2026-06-12Form 42026-06-150001193125-26-271074Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Shefali Agarwal 2026-06-12Form 42026-06-150001193125-26-271079Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Michael Lee 2026-06-12Form 42026-06-150001104659-26-074126Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Redmile Group, LLC 2026-06-12Form 42026-06-150001104659-26-074130Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Yuan Xu 2026-06-12Form 42026-06-150001193125-26-271090Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Laura J. Hamill 2026-06-12Form 42026-06-150001193125-26-271069Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Robert S. Epstein 2026-06-12Form 42026-06-150001193125-26-271083Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Karin Jooss 2026-06-12Form 42026-06-150001193125-26-271088Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Cindy Tahl 2026-08-04Form 42026-08-050001193125-26-335019Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Bahram Valamehr 2026-08-04Form 42026-08-050001193125-26-335007Insider equity transaction reported since the proxy statement. Filing ↗
43Section 06, 2026 voteForm 8-K2026-06-150001193125-26-271055Item 5.07 · say-on-pay result. As reported: 97.03% (votes for as printed: 59,168,689). Filing ↗
44Section 06, 2024 voteForm 8-K2024-06-070001193125-24-157554Item 5.07 · say-on-pay result. As reported: 71.86% (votes for as printed: 65,401,635). Filing ↗
45Section 06, 2023 voteForm 8-K2023-06-090000950170-23-027262Item 5.07 · say-on-pay result. As reported: 96.15% (votes for as printed: 73,720,442). Filing ↗
46Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
47Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
48Section 09b board cost (computed)Computed——Cash 502,249 + equity 0 + all other 0 = 502,249, summed across the director compensation table rows.machine: formula: Σ = 502,249
49Fate Therapeutics (subject), Section 10b CEO totalDEF 14A2026-04-240001193125-26-177094CEO total compensation as printed in Fate Therapeutics's own proxy. As printed: 2,248,568. Filing ↗machine: r2 · c31 · span 391551–391560

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.